BCR-ABL1 Mutation Analysis by Next Generation Sequencing
2008420
Ordering Recommendation
Determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). Test detects all common mutations, including T315I.
Mnemonic
BCRABL NGS
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-12 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavendar (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens. Clotted or serverely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report

See Compliance Statement B: www.aruplab.com/CS  
Note
 
CPT Code(s)
81403
Components
Component Test Code*Component Chart Name
2008421BCR-ABL1 Mutation by NGS Source
2008422BCR-ABL1 Mutation by NGS Result
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis)
  • ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis)
  • BCR-ABL1 Domain Mutation Analysis
  • BCR-ABL1 Mutation (BCR-ABL1 Domain Mutation Analysis)
  • Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation)
  • Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • TKI Therapy Resistance